Skip to main content

Advertisement

SpringerLink
Log in

Gastrointestinal Cancer Therapy and Cardiotoxicity

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion Statement

Gastrointestinal cancers are a heterogenous group of cancers that share common risk factors with cardiovascular disease. Therapy for gastrointestinal cancers have improved cancer-specific outcomes at the cost of cardiotoxicity. The most common cardiotoxic therapies utilized in gastrointestinal cancers include conventional chemotherapy (including fluoropyrimidines and anthracyclines), targeted therapies including anti-vascular endothelial growth factor (VEGF) therapy and tyrosine kinase inhibitors (TKI), and immunotherapy. It is important for clinicians managing patients with gastrointestinal cancers to be aware of potential cardiotoxicity associated with these agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data Availability

No datasets were generated or analysed during the current study.

References and Recommended Reading

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

    Article  PubMed  Google Scholar 

  2. Napier KJ, Scheerer M, Misra S. Esophageal cancer: A Review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointest Oncol. 2014;6(5):112–20.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020;17(8):474–502.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Leiva O, AbdelHameid D, Connors JM, Cannon CP, Bhatt DL. Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2021;3(5):619–34.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Chao A, Thun MJ, Connell CJ, McCullough ML, Jacobs EJ, Flanders WD, et al. Meat consumption and risk of colorectal cancer. JAMA. 2005;293(2):172–82.

    Article  CAS  PubMed  Google Scholar 

  6. Yuhara H, Steinmaus C, Cohen SE, Corley DA, Tei Y, Buffler PA. Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer? Am J Gastroenterol. 2011;106(11):1911–21; quiz 22.

  7. Cook MB, Kamangar F, Whiteman DC, Freedman ND, Gammon MD, Bernstein L, et al. Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. J Natl Cancer Inst. 2010;102(17):1344–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Vogel JD, Felder SI, Bhama AR, Hawkins AT, Langenfeld SJ, Shaffer VO, et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Colon Cancer. Dis Colon Rectum. 2022;65(2):148–77.

    Article  PubMed  Google Scholar 

  9. Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, et al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(3):329–59.

    Article  PubMed  Google Scholar 

  10. Cervantes A, Adam R, Rosello S, Arnold D, Normanno N, Taieb J, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(1):10–32.

    Article  CAS  PubMed  Google Scholar 

  11. Siewert JR, Ott K. Are squamous and adenocarcinomas of the esophagus the same disease? Semin Radiat Oncol. 2007;17(1):38–44.

    Article  PubMed  Google Scholar 

  12. Ajani JA, D’Amico TA, Bentrem DJ, Cooke D, Corvera C, Das P, et al. Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023;21(4):393–422.

    Article  PubMed  Google Scholar 

  13. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.

    Article  PubMed  Google Scholar 

  14. Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, et al. Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17(9):1109–33.

    Article  PubMed  PubMed Central  Google Scholar 

  15. von Mehren M, Kane JM, Riedel RF, Sicklick JK, Pollack SM, Agulnik M, et al. NCCN Guidelines(R) Insights: Gastrointestinal Stromal Tumors, Version 2.2022. J Natl Compr Canc Netw. 2022;20(11):1204–14.

    Article  Google Scholar 

  16. Allen PJ, Kuk D, Castillo CF, Basturk O, Wolfgang CL, Cameron JL, et al. Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarcinoma. Ann Surg. 2017;265(1):185–91.

  17. Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021;18(7):493–502.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, et al. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(4):439–57.

    Article  CAS  PubMed  Google Scholar 

  19. Patrzalek P, Wysokinski WE, Kurmann RD, Houghton D, Hodge D, Kuczmik W, et al. Cancer-associated non-bacterial thrombotic endocarditis-Clinical series from a single institution. Am J Hematol. 2024;99(4):596–605.

    Article  CAS  PubMed  Google Scholar 

  20. Kurmann RD, Klarich KW, Wysokinska E, Houghton D, Kaminska A, Patrzalek P, Hodge D, Wysokinski WE. Echocardiographic findings in cancer-associated non-bacterial thrombotic endocarditis. Clinical series of 111 patients from single institution. Eur Heart J Cardiovasc Imaging. 2024;jeae112. https://doi.org/10.1093/ehjci/jeae112.

  21. Van Cutsem E, Hoff PM, Blum JL, Abt M, Osterwalder B. Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol. 2002;13(3):484–5.

    Article  PubMed  Google Scholar 

  22. Frickhofen N, Beck FJ, Jung B, Fuhr HG, Andrasch H, Sigmund M. Capecitabine can induce acute coronary syndrome similar to5-fluorouracil. Ann Oncol. 2002;13(5):797–801.

    Article  CAS  PubMed  Google Scholar 

  23. Saif MW, Shah MM, Shah AR. Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin Drug Saf. 2009;8(2):191–202.

    Article  CAS  PubMed  Google Scholar 

  24. Zafar A, Drobni ZD, Mosarla R, Alvi RM, Lei M, Lou UY, et al. The Incidence, Risk Factors, and Outcomes With 5-Fluorouracil-Associated Coronary Vasospasm. JACC CardioOncol. 2021;3(1):101–9.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Kosmas C, Kallistratos MS, Kopterides P, Syrios J, Skopelitis H, Mylonakis N, et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol. 2008;134(1):75–82.

    Article  CAS  PubMed  Google Scholar 

  26. Meyer CC, Calis KA, Burke LB, Walawander CA, Grasela TH. Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy. 1997;17(4):729–36.

    Article  CAS  PubMed  Google Scholar 

  27. Wang Y, Wang W, Dong H, Wang G, Chen W, Chen J, et al. Risk factors for fluoropyrimidine-induced cardiotoxicity in colorectal cancer: A retrospective cohort study and establishment of a prediction nomogram for 5-FU induced cardiotoxicity. Front Oncol. 2023;13:1017237.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Jensen SA, Sorensen JB. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol. 2006;58(4):487–93.

    Article  CAS  PubMed  Google Scholar 

  29. Chong JH, Ghosh AK. Coronary Artery Vasospasm Induced by 5-fluorouracil: Proposed Mechanisms, Existing Management Options and Future Directions. Interv Cardiol. 2019;14(2):89–94.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Rajaeinejad M, Parhizkar-Roudsari P, Khoshfetrat M, Kazemi-Galougahi MH, Mosaed R, Arjmand R, et al. Management of Fluoropyrimidine-Induced Cardiac Adverse Outcomes Following Cancer Treatment. Cardiovasc Toxicol. 2024;24(2):184–98.

    Article  CAS  PubMed  Google Scholar 

  31. Zafar A, Drobni ZD, Lei M, Gongora CA, Quinaglia T, Lou UY, et al. The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm. PLoS ONE. 2022;17(4):e0265767.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Leiva O, Bohart I, Ahuja T, Park D. Off-Target Effects of Cancer Therapy on Development of Therapy-Induced Arrhythmia: A Review. Cardiology. 2023;148(4):324–34.

    Article  CAS  PubMed  Google Scholar 

  33. Beitzen-Heineke A, Rolling CC, Seidel C, Erley J, Molwitz I, Muellerleile K, Saering D, Senftinger J, Börschel N, Engel NW, Bokemeyer C, Adam G, Tahir E, Chen H. Long-term cardiotoxicity in germ cell cancer survivors after platinum-based chemotherapy: cardiac MR shows impaired systolic function and tissue alterations. Eur Radiol. 2024;34(6):4102–12. https://doi.org/10.1007/s00330-023-10420-w.

  34. Feng G, Zhou X, Chen J, Li D, Chen L. Platinum drugs-related safety profile: The latest five-year analysis from FDA adverse event reporting system data. Front Oncol. 2023;12:1012093. https://doi.org/10.3389/fonc.2022.1012093.

  35. Ashraf N, Kim R. Treatment of Gastric and Gastroesophageal Cancers—Do We Really Need Anthracyclines? JAMA Oncol. 2017;3(9):1172–3.

    Article  PubMed  Google Scholar 

  36. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973;32(2):302–14.

    Article  CAS  PubMed  Google Scholar 

  37. Radulescu LM, Radulescu D, Ciuleanu TE, Crisan D, Buzdugan E, Romitan DM, Buzoianu AD. Cardiotoxicity associated with chemotherapy used in gastrointestinal tumours. Medicina (Kaunas). 2021;57(8):806. https://doi.org/10.3390/medicina57080806.

  38. Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci. 2020;77(9):1745–70.

    Article  CAS  PubMed  Google Scholar 

  39. Piawah S, Venook AP. Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer. Cancer. 2019;125(23):4139–47.

    Article  PubMed  Google Scholar 

  40. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99(16):1232–9.

    Article  PubMed  Google Scholar 

  41. Touyz RM, Herrmann J. Cardiotoxicity with vascular endothelial growth factor inhibitor therapy. NPJ Precis Oncol. 2018;2:13.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Al-Jazairi AS, Bahammam N, Aljuaid D, Almutairi L, Alshahrani S, Albuhairan N, et al. Cardiovascular adverse events of antineoplastic monoclonal antibodies among cancer patients: real-world evidence from a tertiary healthcare system. Cardiooncology. 2023;9(1):35.

    PubMed  PubMed Central  Google Scholar 

  43. Dobbin SJH, Petrie MC, Myles RC, Touyz RM, Lang NN. Cardiotoxic effects of angiogenesis inhibitors. Clin Sci (Lond). 2021;135(1):71–100.

    Article  CAS  PubMed  Google Scholar 

  44. Vallerio P, Orenti A, Tosi F, Maistrello M, Palazzini M, Cingarlini S, et al. Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: a real-life study and proposed algorithm for proactive management. ESMO Open. 2022;7(1):100338.

    Article  CAS  PubMed  Google Scholar 

  45. Hou W, Ding M, Li X, Zhou X, Zhu Q, Varela-Ramirez A, et al. Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials. J Cancer Res Clin Oncol. 2021;147(8):2407–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.

    Article  CAS  PubMed  Google Scholar 

  47. Gong J, Liu T, Fan Q, Bai L, Bi F, Qin S, et al. Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial. BMC Cancer. 2016;16:68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Henry ML, Niu J, Zhang N, Giordano SH, Chavez-MacGregor M. Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients. JACC Cardiovasc Imaging. 2018;11(8):1084–93.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23(31):7820–6.

    Article  CAS  PubMed  Google Scholar 

  50. Cote GM, Sawyer DB, Chabner BA. ERBB2 inhibition and heart failure. N Engl J Med. 2012;367(22):2150–3.

    Article  CAS  PubMed  Google Scholar 

  51. Soo Park J, Youn JC, Shim CY, Hong GR, Lee CK, Kim JH, et al. Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer. Oncotarget. 2017;8(37):61837–45.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Gurbuz M, Akkus E, Sakin A, Urvay S, Demiray AG, Sahin S, et al. Trastuzumab +/- Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group. J Gastrointest Cancer. 2022;53(2):282–8.

    Article  CAS  PubMed  Google Scholar 

  53. Ishii T, Watanabe T, Higashi T. Baseline cardiac function checkup in patients with gastric or breast cancer receiving trastuzumab or anthracyclines. Cancer Med. 2023;12(1):122–30.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Figure 1 created using BioRender.

Funding

No funding was received for this manuscript.

Author information

Authors and Affiliations

  1. Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, U.S.A.

    Orly Leiva & Jose Alvarez-Cardona

  2. Department of Medicine, Yale New Haven Health, New Haven, CT, U.S.A.

    Talal El Zarif

Authors
  1. Orly Leiva
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Talal El Zarif
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jose Alvarez-Cardona
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

O.L and T.E. wrote the main manuscript text. J.A.C. served as the senior author. O.L. prepared the Figure under the guidance of J.A.C. All authors reviewed the manuscript.

Corresponding author

Correspondence to Jose Alvarez-Cardona.

Ethics declarations

Conflict of Interest

The authors declare no competing interests.

Human and Animal Rights

This article does not contain studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Leiva, O., Zarif, T.E. & Alvarez-Cardona, J. Gastrointestinal Cancer Therapy and Cardiotoxicity. Curr. Treat. Options in Oncol. (2024). https://doi.org/10.1007/s11864-024-01236-x

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11864-024-01236-x

Keywords

Search

Navigation